ASCO 2021 | Genomic profiling in HER2+ disease

Breast cancer is a genetically heterogeneous disease and molecular profiling has become an integral part of disease management. Elisa Agostinetto, MD, Istituto Clinico Humanitas, Rozzano, Milan, Italy, discusses the use of genomic profiling in HER2-positive (HER2+) breast cancer, where several predictive assays are emerging. Dr Agostinetto talks on the potential benefit of combining genomic profiling with traditional clinical and pathological prognostic risk factors into a single integrated model. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.